Humulin M3 (Mixture 3) (Insulin Human)

Humulin M3 is indicated for the treatment of diabetes mellitus in both type 1 and type 2 patients when a mixed insulin regimen is required.

• Provides basal insulin coverage combined with rapid‑acting insulin for mealtime control.
• Used when patients need a predictable insulin profile that covers fasting and post‑prandial glucose.
• Can be part of a basal‑bolus therapy alongside oral antidiabetic agents.
• May be prescribed for adults and adolescents who can self‑inject subcutaneously.
• Adjusted by healthcare professionals based on individual glycemic response.

• Human insulin in Humulin M3 binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, reducing endogenous glucose production and contributing to lower plasma glucose concentrations overall, it helps maintain glycemic control.

Like other insulin preparations, Humulin M3 may be associated with adverse reactions that vary in frequency and severity.

Common

• Low blood sugar (hypoglycemia) presenting as sweating, tremor, or confusion.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy including localized lipoatrophy or lipohypertrophy.
• Weight gain due to improved glucose utilization.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Edema or heart failure exacerbation in susceptible patients.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.

Healthcare providers should evaluate several safety considerations before initiating Humulin M3 therapy.

• Assess renal and hepatic function, as impairment can alter insulin clearance.
• Review history of hypoglycemia unawareness or severe episodes.
• Use caution in pregnant or breastfeeding women; safety data are limited.
• Monitor for signs of cardiovascular disease, especially in patients with edema or heart failure.
• Adjust doses when patients start or stop concomitant medications that affect glucose metabolism.
• Educate patients on proper injection technique and rotation of sites.

Humulin M3 can interact with other medicines, affecting blood glucose control or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment.
• Beta‑blockers that mask hypoglycemia symptoms.
• MAO‑A inhibitors that may potentiate insulin’s glucose‑lowering effect.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which increase hypoglycemia risk.
• Corticosteroids, thiazide diuretics, or growth hormone that may raise glucose levels.
• Alcohol consumption, which can cause delayed hypoglycemia.